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Infectious Disease

Fidaxomicin (Dificid®): New Antibiotic Approved
for the Treatment of Clostridium difficile Infections
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of the program evaluation and at least a 70 percent grade
on the program assessment questions.
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Objectives
After completion of this program, the reader should be able
to:
1. Discuss the symptoms and risk factors associated with
Clostridium difficile associated disease (CDAD).
2. Describe the current guidelines for treatment of CDAD.
3. List the factors contributing to hypervirulent strains of
the disease.
4. Discuss the instances where fidaxomicin may be
preferred for CDAD treatment.

Abstract
Clostridium difficile is a gram-positive, spore forming bacteria

normally transmitted by the fecal-oral route. Infection develops in patients with decreased normal gut flora and is typically associated with recent antibiotic use. Other risk factors
include bowel surgery, compromised immune system function, extended hospital stays, and other underlying diseases.
C. difficile bacteria produce two toxins, which cause increased intestinal fluid secretion and inflammation. Patients
commonly present with diarrhea, abdominal discomfort, loss
of appetite, and nausea. Current treatment guidelines are to
discontinue antimicrobial agents and increase hydration.
Less severe C. difficile associated diarrhea (CDAD) cases are
treated with metronidazole 500 mg three times daily for 10
to 14 days and more severe cases treated with vancomycin
125 mg four times daily for 10 to 14 days. Recently, the FDA
announced approval of Dificid® (fidaxomicin) for treatment
of CDAD. Fidaxomicin is currently dosed 200 mg twice daily
for 10 to 14 days. Several studies have shown fidaxomicin is
non-inferior to vancomycin in treatment of CDAD. For the
purpose of this article, we will further investigate CDAD
treatment guidelines and the effectiveness of fidaxomicin.

Introduction
The recent FDA approval of fidaxomicin has led to a renewed
interest in the treatment of gastrointestinal infections caused
by the bacteria, C. difficile. C. difficile is a gram-positive spore
forming bacteria that causes different diseases via its associated toxin.1 Transmission of the bacteria occurs primarily via
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the fecal-oral route. In normal, healthy patients ingestion of
the bacteria is not harmful because they are protected from
infection by the normal flora of their GI tract as well as antibodies to the most pathogenic C. difficile toxin, Toxin A. The
risk of infection with C. difficile is greatly increased in patients that have received recent antibiotic treatment altering
the bacterial content of the GI tract. The antibiotics most
commonly implicated in the depletion of normal flora include
fluoroquinolones, clindamycin, ampicillin and cephalosporins.
Patients treated with these antibiotics tend to experience
infections soon after the completion of their treatment
course, although studies have reported symptom onset several months after antibiotic use.2 Other common risk factors
include recent GI or bowel surgery, extended inpatient health
care stays, underlying diseases or immunocompromised
states, and advanced age. 3
Clostridium difficile infections originate when the bacteria
passes through the stomach and begins to colonize in the
lower intestinal tract.4 As the bacteria colonize, they release
Toxins A and B, which produce a number of changes in the
surrounding tissue. Toxin A is classified as an enterotoxin
because it produces increased intestinal fluid secretion, promotes mucosa! injury, and can cause inflammation of the GI
tract.1 Toxin A was originally thought to be the causative
agent of COAD, but new research has shown that clinical
symptoms of infection may also be present in Toxin Anegative strains of C. difficile. Although clinical trials have not
yet elucidated which toxin is the root cause of CDAD, the
presence of infection in patients lacking Toxin A may indicate
a larger role of Toxin B than previously thought. Toxin B is
considered a cytotoxin that promotes mucosa! inflammation
and the formation of raised, white-to-yellow pseudomembranous plaques throughout the GI mucosa.1

Patients suffering from CDAD most commonly present with
diarrhea, but symptoms such as abdominal discomfort, nausea, and loss of appetite may also occur.1,3 The diarrhea is
usually watery, possesses a distinct odor, and can occur upwards of 20 times per day. This severe diarrhea may quickly
lead to dehydration and/or electrolyte abnormalities and
should be treated immediately with supplemental fluids and
electrolytes.1 Clinical diagnosis of CDAD requires the patient
to experience at least three unformed stools within a 24-hour
period for greater than two days with no other identifiable
cause.4 C. difficile Toxin A or B must also be detected in a
sample of the patients stool using a polymerase chain reaction. The presence of pseudomembranes in the GI tract may
also be a diagnostic sign of COAD, although it is typically
found in more progressive infections.
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Current Guidelines
The Society of Healthcare Epidemiology of America (SHEA)
and the Infectious Diseases Society of America (IDSA) have
current guidelines regarding the most accepted and effective
options for the treatment of CDAD. These guidelines, determined by the SHEA-IDSA Expert Panel, were formed after
evaluating the best available evidence and practices.s Mild
cases of CDAD can be treated by supportive therapy, including discontinuing the provoking antimicrobial agent and instituting appropriate rehydration.6 Discontinuing the inciting
antimicrobial agent may decrease the risk of CDAD recurrence.s
These guidelines only include two antibiotics (metronidazole
and vancomycin) for treannent of CDAD. These antimicrobial
agents, along with appropriate hygiene and isolation precautions, are the preferred treatment options.6The recommendation for an initial episode of CDAD is oral metronidazole
therapy, while more severe infections are usually treated
with oral vancomycin therapy.1 For patients unable to complete oral therapy for non-severe CDAD, intravenous metronidazole 500 mg three times daily for 10 days is recommended. If the patient has severe CDAD, intravenous tnetronidazole 500 mg three times daily may be administered
with the addition of intracolonic vancomycin 500 mg in 100
mL of normal saline every 4 to 12 hours and/or vancomycin
500 mg four times daily via nasogastric tube.1 Non-oral therapy is advised for patients with severe CDAD, indicated by
paralytic ileus, toxic megacolon, dehydration, sepsis, or the
inability to take oral medications in severely ill or postoperative patients.a Although metronidazole is the least expensive of the two treatments, it is not recommended beyond
the first recurrence of CDAD, due to increased risk of bacterial resistance and the potential for adverse effects due to
widespread systemic absorption.s Treatment with vancomycin is reserved for more severe cases of CDAD, intolerance or
lack of response to metronidazole treatment, or for patients
with a contraindication to metronidazole therapy.6 Due to
the limited therapeutic options for treating CDAD, alternative
approaches are being investigated. Novel antimicrobial
agents, toxin-binding agents, immune modifying agents, probiotics, and fecal replacement therapy are at the forefront of
the current research. A vaccination containing toxoids associated with CDAD is in phase I testing and may prove to be an
area of further development.
Concern About Hypervirulence
Hypervirulent strains of Clostridium difficile are a major concern surrounding CDAD. Spores produced by C. difficile are
often resistant to disinfecting agents and are able to survive
for an extended period of time.9 Hypervirulent strains have
led to an increase in CDAD incidence. The most common hypervirulent strain, ribotype 027 (NAPl/Bl/027), is associated
with increased transmissibility and toxin production. The
incidence of the hypervirulent strains is thought to be associated with frequent quinolone antibiotic treatment. First-line
therapies such as metronidazole have shown decreased clinical efficacy in treating and preventing reinfection by hypervirulent strains.2 Increased colonization of the gut, resistance
to bile salts, transmissibility, motility and chemotaxis may all
play an important role in the emergence of epidemic strains.
Hypervirulent strains may result from bacterial mutations,
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which alter encoded determinants essential to the disease
process. The pathogenesis of C. difficile is an area of active
research, as the mechanisms still remain poorly understood. 6
Together, these factors make the idea of an additional therapeutic agent for the treatment of CDAD very appealing. The
recently approved drug, fidaxomicin, may help fill the role of
an additional treatment for CDAD.
Fidaxomicin
Dificid® (fidaxomicin) is a macrocyclic antibiotic that is bacteriocidal against Clostridium difficile by inhibiting RNA
synthesis in the bacteria via inhibition of RNA polymerase.
Fidaxomicin was approved in 2011 for the treatment of
CDAD in adult patients (18 years or older).10 It represents a
novel treatment for CDAD that may help augment current
therapy. Fidaxomicin has been shown to be as much as eight
times more active than vancomycin against hypervirulent
strains of C. difficile such as NAP1/B1/027, making it a possible treatment alternative in patients who may not respond to
more traditional treatment.11 Currently, the FDA approved
dosing regimen is one 200 mg tablet taken twice daily for ten
days. The results of several clinical trials comparing
fidaxomicin therapy to traditional treatment with vancomycin were pivotal in the approval of this drug for use in CDAD.
Louie, Miller, Mullane, et al. N Engl] Med 2011
The results of a recent study conducted by Louie, et al. comparing fidaxomicin and vancomycin in the treatment of
C. difficile were published in The New England journal of
Medicine in early 2011.11 The objective of the trial was to
compare the safety and efficacy of fidaxomicin and vancomycin in the treatment of CDAD. The phase III trial was a prospective, multi-center, double-blind, randomized, parallelgroup, non-inferiority study conducted throughout 2006 and
2008. A total of 629 patients participated in the study and
received the study medication four times daily for a total of
10 days. Participants must have been at least 16 years of age
with a diagnosis of C. difficile infection. Patients must have
had more than three bowel movements in the 24 hours prior
to randomization. Toxin A or B must have been present in
the stool sample. Patients were excluded from the trial if they
had a severe infection, toxic megacolon, history of colitis or
Crohn's disease, more than one occurrence of CDAD within
three months of study start date, or if they were previously
treated with fidaxomicin. Patients included in the trial received either fidaxomicin 200 mg every 12 hours (with two
intervening placebo doses for appropriate blinding) or vancomycin 125 mg administered every six hours. The patients
were evaluated daily throughout the course of therapy for
cure/failure rate. Once the patients completed the 10-day
course of therapy, they were assessed for signs of COAD recurrence weekly for four weeks. The results of the trial found
that fidaxomicin was noninferior to vancomycin in treating
CDAD. Fidaxomicin therapy was associated with a significantly lower recurrence rate than vancomycin therapy. Furthermore, fidaxomicin was found to have significantly higher
global cure rates than vancomycin. The median time to resolution of diarrhea was also decreased in the fidaxomicin
group, although the differences were not found to be significant. The two treatment groups displayed no significant
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differences in adverse events and serious adverse events
throughout the course of therapy. The results of this trial
indicated fidaxomicin exhibits clinical noninferiority to vancomycin for the treatment of CDAD, with both drugs expressing a similar side effect profile. The strength of this trial was
the randomized, double-blind, multi-center study design. It
also included appropriate inclusion and exclusion criteria
and appropriate randomization of the patients. The trial was
of adequate length in order to effectively treat the patients
and follow up for recurrence of infection. Some limitations of
the trial were the limited study population and bias associated with noninferiority trials.
Mullane, Miller, Weiss, et al. Clin Infect Dis 2011

Subjects from two prospective, double-blind, randomized,
parallel-group, noninferiority studies were pooled to assess
the adverse effects on clinical outcomes of C. difficile infection associated with concomitant antibiotic therapy.12 Eligible participants were at least 16 years old and were diagnosed with first episode of CDAD or first recurrence of CDAD
within three months of the beginning of the study. Subjects
were also eligible if they had been treated with metronidazole for greater than three days without any improvement.
For the purpose of this study, COAD was defined as a change
in bowel habits with greater than three unformed bowel
movements during the 24 hours before randomization and
presence of either C. difficile Toxin A or B in stool within 48
hours before randomization.
Study participants were randomized to receive either fidaxomicin 200 mg twice daily or vancomycin 125 mg four
times daily for 10 days. The study drugs were encapsulated
to achieve double blinding. CDAD cure was defined as resolution of diarrhea until two days after end of therapy. Failure
was defined as persistent diarrhea and/or need for additional CDAD therapy. Clinical cure patients had a follow up
visit at the end of the study for evidence of recurrence and
determination of global cure. The antibiotics with increased
risk for contribution to CDAD were identified and categorized with concomitant antibiotics (CA) for each participant.
A total of 1,164 patients were enrolled with 999 evaluable
for clinical and global cure. In the population of 999 evaluable participants, 275 received CA during some point during
the study and 192 received CA during CDAD therapy. Clinical
cure was achieved by 92.57 percent with no CA use and
84.38 percent with CA use, while global cure rates were
74.72 percent and 65.82 percent respectively. Fidaxomicin
and vancomycin were comparable in clinical cure rates, 92.3
percent and 92.8 percent respectively, with no CA use. When
using CA, fidaxomicin clinically cured 90 percent versus 79.4
percent with vancomycin (P=0.04). Fidaxomicin had significantly better rates of global cure with 72.7 percent versus
59.4 percent in vancomycin (P=0.02) patients with CA use.
Fidaxomicin also had significantly lower rates of recurrence
compared to vancomycin in patients receiving no CA during
study (11.5 percent versus 23.9 percent, P<0.001). This
study indicates that COAD treatment, while also having CA,
decreases the efficacy of CDAD therapy. Overall, administration of CA reduced vancomycin clinical cure rate (92.8 per-
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cent to 79.4 percent, P=0.04) while fidaxomicin was unchanged (92.3 percent versus 90 percent). This may suggest
that fidaxomicin is more effective in treatment of COAD with
administration of CA. Current guidelines recommend discontinuation of CA while undergoing CDAD treatment, yet frequently patients must take CA for treatment of concurrent
systemic infections. Taking a CA while receiving treatment
with fidaxomicin or vancomycin reduced cure rate about 8
percent and prolonged time to resolution by 43 hours. However if a CA is necessary, fidaxomicin might be preferred to
vancomycin in treatment of CDAD.
Pharmacoeconomics and Potential Guideline Updates
Economic considerations regarding the selection of antimicrobial agents have been a serious topic surrounding C. difficile treatment. The Infectious Disease Alert published a cost
consideration article in 2011 detailing the clinical and cost
considerations of the medications approved for the treatment of C. difficile. The wholesale price of the generic metronidazole tablet is $0.07.14 A 10-day course of metronidazole treatment would cost $2.10. Vancomycin is available in
125 mg and 250 mg capsules under the brand name Vancocin®. The cost per capsule is $26.52 and $48.93, respectively.
A 10-day course ofVancocin® therapy would cost $1,061 and
$3,914, respectively. Diluting vancomycin intravenous solution with 10 mL of normal saline for oral solution would significantly reduce medication costs. One 500 mg vial costs
$2.21; the 10-day course of therapy would be approximately
$88. One 200 mg fidaxomicin tablet costs $140; the 10-day
course of therapy would cost $2,800. While fidaxomicin may
be proven to be a more efficacious drug, the cost is significantly higher than vancomycin. The higher efficacy of fidaxomicin and lower recurrence rates indicate that despite
the higher cost, fidaxomicin may be first line therapy for
CDAD in patients who are at high risk for complications and
recurrent infections. Although the cost associated with
fidaxomicin therapy may not allow it to be a universal
first-line medication, its use in special populations and for
patients with a high risk of recurrent infections may prove to
be more economically favorable than metronidazole or vancomycin.
Conclusions
Recently the FDA approved fidaxomicin for the treatment of
C. difficile infections. Infection from C. difficile typically arises
following antibiotic use because of the loss of normal gut
flora. The most common symptom is diarrhea, but abdominal
discomfort can also be present. Current treatment guidelines
indicate mild COAD should be treated with metronidazole
500 mg three times daily for 10 to 14 days and more severe
cases treated with vancomycin 125 mg four times daily for
10-14 days. The new antibiotic, fidaxomicin, is a bacteriocidal macrocyclic antibiotic effective against C. difficile. Studies have shown that fidaxomicin is noninferior to vancomycin in treating CDAD, both in patients with and without CA
use. Two studies have examined the effectiveness of
fidaxomicin versus vancomycin, and have shown that
fidaxomicin may be associated with lower rates of recurrence compared to vancomycin. Results also indicate that
fidaxomicin may have a shorter time to resolution of diar-
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rhea compared to vancomycin. There is no statistical difference between adverse events with fidaxomicin compared to
vancomycin. Further studies are necessary for comparing
fidaxomicin and vancomycin effectiveness. In concordance
with current guidelines, metronidazole and vancomycin
should remain first line of treatment. Although more
expensive, the use of fidaxomicin may provide benefit when
first-line treatment with vancomycin is ineffective.
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Assessment Questions
1. Which of the following is NOT a risk factor for developing
CDAD?
a. Immmunocompromised condition
b. Previous antibiotic use
c. Hemorrhagic stroke
d. Advanced age
2. According to the current guidelines, all of the following are
treatment options for C. difficile EXCEPT:
a. Withdrawal of current antibiotics for mild cases
of the disease
b. Clindamycin
c. Metronidazole
d. Vancomycin
3. In the Louie, Miller, Mullane, et al. trial, fidaxomicin was
found to be:
a. Noninferior to vancomycin in the clinical cure of
C. difficile
b. Associated with a significantly lower recurrence
rate than vancomycin
c. Associated with a significantly higher global cure
rate than vancomycin
d. All of the above
4. What factor most influences the risk of recurrence of C.
difficile?
a. Antibiotic use during follow-up period
b. Use of concomitant antibiotics during treatment
c. Initial fidaxomicin treatment
d. Initial vancomycin treatment
5. Which of the following is NOT a potential factor in the
emergence of epidemic strains:
a. Fecal transplantations
b. Chemotaxis
c. Increased colonization of the gut
d. Resistance to bile salts

8. Dificid® (fidaxomicin) should be considered when:
a. Patient has a high risk of CDAD recurrence
b. Patient is currently using concomitant antibiotics
c. Vancomycin and metronidazole therapy is
ineffective
d. All of the above
9. The FDA approved dosing regimen for Dificid®
(fidaxomicin) in CDAD is
for 10 days.
a. 100 mg once daily
b. 500 mg twice daily
c. 200 mg twice daily
d. 1 gm three times daily
10. All of the following are common symptoms of CDAD except:
a. Diarrhea
b. Respiratory tract infection
c. Nausea
d. Abdominal discomfort

Ohio Northern University is accredited by the
Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education. This
program is eligible for credit until 11129/ 14.

To receive continuing education credit for this program, you
must answer the above questions and fill out the evaluation
form. Please visit www.onu.edu/pharmacy to enter the required information. Please allow two to three weeks for
electronic distribution of your continuing education certificate, which will be sent to your valid email address in PDF
format.

6. In the Mullane, Miller, Weiss, et al. trial, fidaxomicin was
shown to be:
a. Noninferior to vancomycin in clinical cure with
CA use
b. Associated with a significantly higher recurrence
rate than vancomycin
c. Associated with a significantly lower global cure
rate than vancomycin
d. Associated with significantly more side effects
than vancomycin
7. If a patient is unable to use oral therapy, what is the current approved replacement therapy?
a. 500 mg fidaxomicin IV every 4 hours
b. 500 mg vancomycin IV every 4 hours
c. 500 mg metronidazole IV three times daily
d. 500 mg clindamycin IV three times daily
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